POWER 3 MEDICAL PRODUCTS nahe am Allzeittief - 500 Beiträge pro Seite

[farfaraway]

POWER 3 MEDICAL PRODUCTS (OTCBB:PWRM) bekommt wieder Momentum Nahe am Allzeittief.

[farfaraway]

[farfaraway]

Free Power 3 Medical Prod Stock Charts
Power 3 Medical Prod Historical Stock Chart
Power 3 Medical Prod Historical Stock Chart

[farfaraway]

Power3 Medical Products, Inc plant mit Rozetta-Cell Life Sciences, Inc einen Zusammenschluss. Dieser muss allerdings von den Aktionären erstmal bewilligt werden. Beide Firmen passen zusammen, Synergien werden sicher frei werden. Power 3 hat Patente für Biotracer während Rozetta-Cell auf Stammzellen spezialisiert ist.


Company Overview Rozetta-Cell Life Sciences, Inc.: is a biotechnology company specializing in the delivery and imaging of stem cells during therapy. The company was incorporated in 2010 and is based in the United States.

Ankündigung:

SPECIAL MEETING OF SHAREHOLDERS
MERGER PROPOSED—YOUR VOTE IS VERY IMPORTANT

Dear Shareholder:

You are cordially invited to attend a special meeting of shareholders of Power3 Medical Products, Inc. (“Power3”) to be held on _______________, 2011 at _____ a.m., local time, at the offices of Power3, 26022 Budde Road, The Woodlands, Texas 77380. At the special meeting, you will be asked to consider and vote upon, among other proposals, an Agreement and Plan of Merger dated as of September 7, 2010 and amended December 31, 2010 (as amended, the “merger agreement”) between Power3 and Rozetta-Cell Life Sciences, Inc. (“Rozetta-Cell”) pursuant to which Rozetta-Cell will merge with and into Power3, with Power3 remaining as the surviving company.

If the merger is consummated, Rozetta-Cell will merge with and into Power3 and Power3 will remain as the surviving company. All outstanding shares of Rozetta-Cell common stock will be converted into the right to receive shares of Power3 common stock. Power3 will issue a total of 1,000,000,000 shares of common stock to the Rozetta-Cell shareholders representing approximately 68% of the outstanding shares of the combined company immediately following the consummation of the merger.

The board of directors of Power3 has determined that it is in the best interests of the shareholders to enter into the merger agreement and has approved and declared advisable the merger agreement. The board of directors of Power3 made its determination after consideration of a number of factors more fully described in this proxy statement. The board of directors of the Power3 recommends that you vote “FOR” approval of the proposal to adopt the merger agreement and “FOR” approval of the proposal to adjourn the special meeting, if necessary or appropriate, to solicit additional proxies.

Your vote is very important. Whether or not you plan to attend the special meeting, please complete, date, sign and return, as promptly as possible, the enclosed proxy card in the accompanying prepaid reply envelope. If you attend the special meeting and vote in person, your vote by ballot will revoke any proxy previously submitted. The failure to vote your shares of our common stock will have the same effect as a vote “AGAINST” the proposal to adopt the merger agreement.





The accompanying proxy statement provides you with detailed information about the special meeting, the merger agreement and the merger. We encourage you to read the entire proxy statement and its annexes, including the merger agreement, carefully. You may also obtain additional information about Power3 from documents that we have filed with the Securities and Exchange Commission.

Thank you in advance for your cooperation and continued support.

/s/ Ira L. Goldknopf

Ira L. Goldknopf
President and Chief Scientific Officer

[farfaraway]

Das wesentliche zu PWRM: Power 3 hat Anfang 2010 insgesamt 47 Biomarker als Patent angemeldet. Bis allerdings diese von der Behörde anerkannt werden, wird noch einige Zeit verstreichen.

Darüber hinaus gibt es bereits ein Bio-Marker namens BC-SeraPro, mit dessen Hilfe aus dem Blut von Probanden Hinweise auf Brustkrebs im frühen Vorfeld zu finden sind.

Originaltext zu den eingereichten Patenten im Frühjahr 2010:

Power3 Medical Products Inc. has filed a U.S. utility patent application for 47 protein biomarkers in human blood that the company said are indicators of specific neurodegenerative diseases.

The Houston-based biotech company (OTCBB: PWRM) based its patent applications on findings in blood serum samples from more than 750 neurodegenerative disease patients as well as normal control subjects.

The results showed that the biomarkers are useful in the diagnosis of Alzheimer's disease, non-Alzheimer's dementias, Parkinson's disease and ALS (Lou Gehrig's disease).

Eighteen million people worldwide have Alzheimer's disease, but because the early signs are often hard to distinguish from normal signs of aging, many patients are not diagnosed until the neuronal damage caused by the disease is extensive.

"One of the most critical issues in the diagnosis of Alzheimer's disease is the ability to distinguish AD from other forms of dementia and other neurological and vascular disorders," said Dr. Ira Goldknopf, Power3's director of proteomics and senior inventor.

"Power3's group of protein biomarkers in blood serum can be employed for such a differential diagnosis, which will accelerate both the diagnosis and the delivery of treatment."

Read more: Power3 files for patent application | Houston Business Journal

[farfaraway]

http://bigcharts.marketwatch.com/charts/big.chart?symb=pwrm&…

[farfaraway]

http://bigcharts.marketwatch.com/charts/big.chart?symb=pwrm&…

[farfaraway]

[farfaraway]